Beta Bionics has been launched as a public benefit corporation to commercialise automated bihormonal pumps for type 1 diabetes sufferers.
Boston University today revealed it has spun out Beta Bionics, a US-based public benefit corporation that will commercialise an automated dosage mechanism for sufferers of type 1 diabetes.
Beta Bionics is developing a bihormonal pump dubbed iLet which automatically judges how much insulin and glucagon should be administered to those with the autoimmune disease.
The pump will undergo initial home-use trials on children and adults later in 2016, to be partially funded by a $1.5m grant from the US government-owned…
